ArticleBMC immunology2026
Clinical characteristics and risk factors of cytomegalovirus infection in patients with good syndrome.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGood Syndrome (GS) is a rare immunodeficiency disorder classically defined by the triad of thymoma, hypogammaglobulinemia, and recurrent infections. Cytomegalovirus (CMV) infection is the most frequently reported viral infection in patients with GS. This study aimed to characterize the clinical features and immunological alterations in patients with GS complicated by CMV infection.
methodsWe conducted a retrospective cohort study of GS patients with or without CMV infection at Peking Union Medical College Hospital from January 2015 to December 2024. Logistic regression and COX proportional hazards regression model were employed to identify potential risk factors for CMV infection and prognostic factors of overall survival among GS patients.
resultsAmong the 27 enrolled patients, 15 developed CMV infection: 1 presented with CMV pneumonia, 6 was clinically diagnosed with CMV pneumonia, 6 with isolated CMV DNAemia, 1 with CMV colitis, and 1 with CMV retinitis. Peripheral blood CD4 + T-cell counts were significantly lower in the CMV group than non-CMV group (156 [116-210] vs. 374 [200-443] cells/µL; P < 0.05). The CMV group exhibited a higher rate of glucocorticoid (GC) use, greater cumulative GC exposure prior to diagnosis, and higher frequencies of respiratory pathogen isolation and fungal infection compared with the non-CMV group. Multivariable logistic regression identified lower serum albumin (P = 0.012; OR, 0.743; 95% CI: 0.58-0.938) and lower serum IgG (P = 0.041; OR, 0.565; 95% CI: 0.327-0.978) as potential risk factors for CMV infection in GS patients.
conclusionGS patients with CMV infection exhibited lower lymphocyte counts, higher glucocorticoid administration rate and increased susceptibility to respiratory and opportunistic fungal infections. During active CMV infection, these patients consistently displayed CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.